Golimumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1756 publications

Efficacy and safety of subcutaneous golimumab in Syrian patients with ankylosing spondylitis: A cohort study.

Efficacy and safety of subcutaneous golimumab in Syrian patients with ankylosing spondylitis: A cohort study.

Journal: The Journal of international medical research

Published: August 22, 2026

Efficacy and safety of golimumab biosimilar BAT2506 in patients with active psoriatic arthritis after switching from reference golimumab: 52-week results of a phase 3, double-blind, randomized study.

Efficacy and safety of golimumab biosimilar BAT2506 in patients with active psoriatic arthritis after switching from reference golimumab: 52-week results of a phase 3, double-blind, randomized study.

Journal: Expert opinion on biological therapy

Published: August 19, 2026

Nocardia farcinica septic bursitis - a case report and scoping literature review.

Nocardia farcinica septic bursitis - a case report and scoping literature review.

Journal: Swiss medical weekly

Published: July 31, 2026

Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

Real-world effectiveness and safety of golimumab in ulcerative colitis: multicenter experience from Chile.

Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru

Published: July 25, 2026

Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Effectiveness and Challenges in a Moroccan Tertiary Care Center.

Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Effectiveness and Challenges in a Moroccan Tertiary Care Center.

Journal: Cureus

Published: July 19, 2026

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: July 13, 2026

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study: Erratum.

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study: Erratum.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: July 02, 2026

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study: Erratum.

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study: Erratum.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: July 02, 2026

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Journal: Expert opinion on biological therapy

Published: June 28, 2026

Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization.

Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization.

Journal: Antibodies (Basel, Switzerland)

Published: June 17, 2026

Golimumab in Treatment-Refractory Hidradenitis Suppurativa.

Golimumab in Treatment-Refractory Hidradenitis Suppurativa.

Journal: JAMA dermatology

Published: June 10, 2026

Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits.

Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits.

Journal: Advances in therapy

Published: May 27, 2026

Showing 1-12 of 1,756

Last Updated: 09/26/2026